Back to News
Market Impact: 0.4
Jazz Pharmaceuticals Completes $820M Acquisition Of Actio Biosciences; Adds KCNT1 Epilepsy Therapy
Source: Nasdaq
M&A & RestructuringHealthcare & BiotechPrivate Markets & Venture
Jazz Pharmaceuticals completed its acquisition of privately held Actio Biosciences for $820 million upfront. The deal expands Jazz's rare-disease-focused biopharmaceutical portfolio and is likely to be a meaningful company-specific strategic development.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
JAZZ0.50
More News
- Grab aims for 'next level' in financial services with purchase of buy-now pay-later platform Atome
- Exclusive-Malaysia talks to rival airlines as it monitors AirAsia’s financial health, sources say
- BlackRock’s Fink, Blackstone’s Gray Back Carney’s Canada Investment Push
- Factbox-Private equity, foreign investors fuel Aussie M&A activity in 2026
- Axon prices $1 billion convertible notes offering due 2031
- Australia’s Reliance Worldwide agrees to Brookfield’s $2.9 billion buyout bid